Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein

Vaccine

Volumn 23, Issue 39, 2005, Pages 4793-4803

  Dela Cruz, Jay S ^a   Morrison, Sherie L ^a   Penichet, Manuel L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody; Cytokine; Vaccine

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 2; TRASTUZUMAB; TUMOR ANTIGEN; CANCER VACCINE; IMMUNOGLOBULIN G; RECOMBINANT VACCINE;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; IMMUNOLOGY;

ANIMALS; B-LYMPHOCYTES; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; VACCINATION; VACCINES, SYNTHETIC;

EID: 25144495292     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.04.041     Document Type: Article

References (58)

1. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001;10(3):139-52.
2. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001;61(Suppl. 2):1-13.
3. Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001;7(9):2703-11.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177-82.
5. Crino L, Franceschi E, Scopece L. HER-2 inhibitors: clinical results. Suppl Tumori 2002;1(6):3-4.
6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92.
7. Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol 1996;156(9):3151-8.
8. Visco V, Bei R, Moriconi E, Gianni W, Kraus MH, Muraro R. ErbB2 immune response in breast cancer patients with soluble receptor ectodomain. Am J Pathol 2000;156(4):1417-24.
9. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5(6):1289-97.
10. Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, et al. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 2003;9(15):5559-65.
11. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96(9):3102-8.
12. Dela Cruz JS, Lau SY, Ramirez EM, De Giovanni C, Forni G, Morrison SL, et al. Protein vaccination with the HEK2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine 2003;21(13-14):1317-26.
13. Chen J, Trounstine M, Alt FW, Young F, Kurahara C, Loring JF, et al. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int Immunol 1993;5(6):647-56.
14. Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165(9):5133-42.
15. Helguera G, Penichet ML. Antibody-cytokine fusion proteins for the therapy of cancer. Methods Mol Med 2005;109:347-74.
16. Penichet ML, Dela Cruz JS, Shin SU, Morrison SL. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum Antibodies 2001;10(1):43-9.
17. Dela Cruz JS, Trinh KR, Morrison SL, Penichet ML. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J Immunol 2000;165(9):5112-21.
18. Arens R, Schepers K, Nolte MA, van Oosterwijk MF, van Lier RA, Schumacher TN, et al. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med 2004;199(11):1595-605.
19. Qin Z, Harders C, Cao X, Huber C, Blankenstein T, Seliger B. Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors. Cancer Res 2002;62(10):2856-60.
20. Tumpey TM, Renshaw M, Clements JD, Katz JM. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 2001;75(11):5141-50.
21. van Der Most RG, Murali-Krishna K, Ahmed R, Strauss JH. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J Virol 2000;74(17):8094-101.
22. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999;17(3):253-8.
23. Chen TT, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 1994;153(10): 4775-87.
24. Hazama M, Mayumi-Aono A, Asakawa N, Kuroda S, Hinuma S, Fujisawa Y. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2. Vaccine 1993;11(6):629-36.
25. Hazama M, Mayumi-Aono A, Miyazaki T, Hinuma S, Fujisawa Y. Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2. Immunology 1993;78(4):643-9.
26. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993;362(6422):755-8.
27. Harvill ET, Fleming JM, Morrison SL. In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. J Immunol 1996;157(7):3165-70.
28. Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, van Schip JJ, Sedlik C, Melief CJ, et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 2002;168(5):2240-6.
29. Baiu DC, Prechl J, Tchorbanov A, Molina HD, Erdei A, Sulica A, et al. Modulation of the humoral immune response by antibody-mediated antigen targeting to complement receptors and Fc receptors. J Immunol 1999;162(6):3125-30.
30. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 1998;95(2):652-6.
31. Morrison SL, Terres G. Enhanced immunologic sensitization of mice by the simultaneous injection of antigen and specific antiserum. II. Effect of varying the antigen-antibody ratio and the amount of immune complex injected. J Immunol 1966;96(5):901-5.
32. Perkins KA, Chain BM. Presentation by peritoneal macrophages: modulation by antibody-antigen complexes. Immunology 1986;58(1):15-21.
33. Virgin HWt, Kurt-Jones EA, Wittenberg GF, Unanue ER. Immune complex effects on murine macrophages. II. Immune complex effects on activated macrophages cytotoxicity, membrane IL, 1 and antigen presentation. J Immunol 1985;135(6):3744-9.
34. Anderson CF, Mosser DM. Cutting edge: biasing immune responses by directing antigen to macrophage Fc gamma receptors. J Immunol 2002;168(8):3697-701.
35. Yada A, Ebihara S, Matsumura K, Endo S, Maeda T, Nakamura A, et al. Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB- and FcgammaRI/III-mediated immune complex uptake. Cell Immunol 2003;225(1):21-32.
36. Dela Cruz JS, Trinh KR, Chen HW, Ribas A, Morrison SL, Penichet ML. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies. Mol Immunol, in press.
37. Larregina AT, Morelli AE, Kolkowski E, Sanjuan N, Barboza ME, Fainboim L. Pattern of cytokine receptors expressed by human dendritic cells migrated from dermal expiants. Immunology 1997;91(2):303-13.
38. Yamada K, Yamakawa M, Imai Y, Tsukamoto M. Expression of cytokine receptors on follicular dendritic cells. Blood 1997;90(12):4832-41.
39. Lindencrona JA, Preiss S, Kammertoens T, Schuler T, Piechocki M, Wei WZ, et al. CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2004;109(2):259-64.
40. Nanni P, Landuzzi L, Nicoletti G, De Giovanni C, Rossi I, Croci S, et al. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol 2004;173(4):2288-96.
41. Kim KM, Shin EY, Moon JH, Heo TH, Lee JY, Chung Y, et al. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen. Int J Cancer 2002;102(4):428-34.
42. Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 2001;194(9):1195-205.
43. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003;8(3):237-49.
44. Chin YE, Kitagawa M, Kuida K, Flavell RA, Fu XY. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 1997;17(9):5328-37.
45. Thornton S, Kuhn KA, Finkelman FD, Hirsch R. NK cells secrete high levels of IFN-gamma in response to in vivo administration of IL-2. Eur J Immunol 2001;31(11):3355-60.
46. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003;101(8): 3052-7.
47. Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E, et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 2003;111(8):1161-70.
48. Constant SL. B lymphocytes as antigen-presenting cells for CD4+ T cell priming in vivo. J Immunol 1999;162(10):5695-703.
49. Liu Y, Wu Y, Ramarathinam L, Guo Y, Huszar D, Trounstine M, et al. Gene-targeted B-deficient mice reveal a critical role for B cells in the CD4 T cell response. Int Immunol 1995;7(8):1353-62.
50. Joao C, Ogle BM, Gay-Rabinstein C, Platt JL, Cascalho M. B cell-dependent TCR diversification. J Immunol 2004;172(8):4709-16.
51. Cascalho M, Platt JL. B cell-dependent T cell development. Acta Paediatr Suppl 2004;93(445):52-3 [discussion 54].
52. Caulfield MJ, Stanko D. T-cell dependent response to immune complexes abrogates B-cell unresponsiveness to pneumococcal cell wall polysaccharide. Immunology 1995;86(3):331-5.
53. Nemazee DA. Immune complexes can trigger specific, T cell-dependent, autoanti-IgG antibody production in mice. J Exp Med 1985;161(1):242-56.
54. Nordstrom E, Moller E, Abedi-Valugerdi M. Induction of IgG rheumatoid factor (RF) production by antibody-antibody (RF-like) immune complexes: the role of T cells, complement and Fc gamma receptors. J Autoimmun 1998;11(2):131-40.
55. Wen YM, Guo SQ, Zhang W, Yan XH, Li PY. Enhanced immunogenicity in mice with hepatitis B vaccine complexed to human hepatitis B immunoglobulin. Chin Med J (Engl) 1994;107(10):741-4.
56. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4(10):762-74.
57. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;100(14):8372-7.
58. Wei WZ, Morris GP, Kong YC. Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 2004;53(2):73-8.